Sorry, you need to enable JavaScript to visit this website.

Official Consumer Website | TECVAYLI® (teclistamab-cqyv)

People icon

TECVAYLI® is a prescription medicine to treat adults with multiple myeloma who:

  • have already received at least 4 treatment regimens, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody to treat their multiple myeloma, and
  • their cancer has come back or did not respond to prior treatment

TECVAYLI® was approved based on patient responses. There are ongoing studies to confirm the clinical benefit of TECVAYLI®.

It is not known if TECVAYLI® is safe and effective in children.

See results from the TECVAYLI® clinical trial

TECVAYLI® is the first treatment of its kind for multiple myeloma—it’s called a bispecific antibody, and it works by binding to both multiple myeloma cells as well as T-cells to help your immune system recognize the multiple myeloma cells and destroy them.

Cartoon t-cell and multiple myeloma cell

Learn more about how TECVAYLI® works

TECVAYLI® was studied in 110 adults, 78% of whom had already been on at least 4 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

More than half of adults saw results with TECVAYLI® in the clinical trial

0.62
  • 62% of people in the clinical trial who took TECVAYLI® responded
    • 28% of people taking TECVAYLI® had a complete response or better to treatment
    • 29% of people taking TECVAYLI® had a very good partial response, and 5% had a partial response
  • Median time to first response with TECVAYLI® was 1.2 months (response times ranged from 0.2 months to 5.5 months)

Talk to your doctor for more information about response.

Learn more about the effectiveness of TECVAYLI®

RESPONSE WITH TECVAYLI® 62% of people in the clinical trial who took TECVAYLI® responded.

SUBCUTANEOUS INJECTION TECVAYLI® is given by a doctor or nurse as a subcutaneous injection under the skin, usually in your stomach area (abdomen), your thigh, or another area of your body.

WORKS DIFFERENTLY TECVAYLI® works by binding to both multiple myeloma cells as well as T-cells to help your immune system recognize the multiple myeloma cells and destroy them.

Learn more about TECVAYLI®

If your multiple myeloma is refractory or relapsed, ask your healthcare provider if TECVAYLI® is right for you.

Steps to talking to your doctor about TECVAYLI® (teclistamab-cqyv)

Learn more about TECVAYLI®

Man in blue t-shirt with arms folded staring to his left Play button icon

MEET MIKE

Yellow quotation marks

I have the greatest support staff—my amazing wife, my children, my parents, my family.

Yellow quotation marks

home-gradient-short

Mike is a real patient who’s been living with multiple myeloma for over 8 years. Listen as he and his wife discuss his journey from diagnosis through relapse, as well as their relationship as both husband and wife and patient and caregiver.

Mike received TECVAYLI®

 

Once you and your doctor have decided that TECVAYLI® is right for you, Janssen has resources to help support your treatment journey.

Personalized one-on-one support

Starting and staying on track with a new medication can feel overwhelming. A Janssen Compass® Care Navigator is here to help with free personalized one-on-one support over the phone throughout your treatment journey.

You will talk to the same Care Navigator on every phone call. They will help you in 3 key areas:

  • Explore options that may help you pay for your medication
  • Learn more about your cancer and Janssen medication
  • Find resources for your practical and emotional needs while coping with cancer

Janssen Compass® is limited to education about your Janssen therapy, its administration, and/or your disease. It is intended to supplement your understanding of your therapy and is not intended to provide medical advice, replace a treatment plan from your doctor or nurse, or serve as a reason for you to start or stay on this medication.